Stock of the Day
January 20, 2023
Zymeworks (ZYME)
$11.85
-$0.17 (-1.4%)
Market Cap:
$824.49M
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Recent News
Zymeworks May 2025 slides: Pipeline expansion amid modest revenue growth
(investing.com)
Zymeworks Inc. Reports Financial Results and Highlights Recent Developments, Including Appointment of Dr. Sabeen Mekan and AACR Poster Presentations
(nasdaq.com)
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript
(msn.com)
Zymeworks Inc.: Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
(finanznachrichten.de)
Zymeworks outlines robust pipeline advancements and financial resilience through 2027
(msn.com)
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
(finance.yahoo.com)
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
(seekingalpha.com)
Zymeworks Inc. 2025 Q1 - Results - Earnings Call Presentation
(seekingalpha.com)
Jazz Pharmaceuticals Stock Price, Quotes and Forecasts
(benzinga.com)